STAAR Surgical Co
NASDAQ:STAA

Watchlist Manager
STAAR Surgical Co Logo
STAAR Surgical Co
NASDAQ:STAA
Watchlist
Price: 23.12 USD -3.18%
Market Cap: 1.1B USD
Have any thoughts about
STAAR Surgical Co?
Write Note

STAAR Surgical Co
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

STAAR Surgical Co
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
STAAR Surgical Co
NASDAQ:STAA
Additional Paid In Capital
$466.6m
CAGR 3-Years
8%
CAGR 5-Years
9%
CAGR 10-Years
10%
Haemonetics Corp
NYSE:HAE
Additional Paid In Capital
$544.4m
CAGR 3-Years
-1%
CAGR 5-Years
0%
CAGR 10-Years
3%
ICU Medical Inc
NASDAQ:ICUI
Additional Paid In Capital
$1.4B
CAGR 3-Years
25%
CAGR 5-Years
16%
CAGR 10-Years
31%
Align Technology Inc
NASDAQ:ALGN
Additional Paid In Capital
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Lantheus Holdings Inc
NASDAQ:LNTH
Additional Paid In Capital
$797.4m
CAGR 3-Years
5%
CAGR 5-Years
26%
CAGR 10-Years
22%
Merit Medical Systems Inc
NASDAQ:MMSI
Additional Paid In Capital
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

STAAR Surgical Co
Glance View

Market Cap
1.1B USD
Industry
Health Care

In the early throes of medical innovation, STAAR Surgical Co. carved a niche within the ophthalmic industry, where its focus on implantable lenses set it apart from many contemporaries. Based in Monrovia, California, the company began its journey by enhancing an integral component of human life: vision. Through the skillful development and manufacture of implantable collamer lenses (ICLs), STAAR Surgical has thrived by providing solutions for those seeking alternatives to laser-based surgeries. Its ICL technology directly targets issues like myopia (nearsightedness) and astigmatism, offering patients a reversible, less invasive option than traditional corrective procedures. STAAR Surgical's business model hinges on a blend of specialized technology and strategic market penetration. The company primarily generates revenue by selling its suite of implantable lenses to healthcare providers and clinics worldwide, capitalizing on the rising trend of elective vision correction procedures. With its innovation-driven credo, STAAR continually invests in R&D to enhance its product offerings, ensuring it remains at the forefront of eye-care technology. By targeting emerging markets and expanding its global footprint, particularly in regions with growing demand for premium vision solutions, STAAR has positioned its unique value proposition to capitalize on both technological advancements and changing patient preferences. Through this deliberate strategy, STAAR not only bolsters its revenue streams but also fortifies its presence as a key player in the ophthalmic landscape.

STAA Intrinsic Value
26.42 USD
Undervaluation 13%
Intrinsic Value
Price

See Also

What is STAAR Surgical Co's Additional Paid In Capital?
Additional Paid In Capital
466.6m USD

Based on the financial report for Sep 27, 2024, STAAR Surgical Co's Additional Paid In Capital amounts to 466.6m USD.

What is STAAR Surgical Co's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
10%

Over the last year, the Additional Paid In Capital growth was 7%. The average annual Additional Paid In Capital growth rates for STAAR Surgical Co have been 8% over the past three years , 9% over the past five years , and 10% over the past ten years .

Back to Top